Our Story

In 2021, the founders Liam and Lachlan set out to revolutionise the way people manage allergies. By developing a novel drug delivery platform, they ensured that adrenaline could be carried in a seamless and integrated fashion, making burdensome auto-injectors a thing of the past.

 

With the support of global experts, AdraCard has progressed rapidly into 2024. Our team and partners are proud of their recent efforts and looks forward to disclosing more as we bridge the gap from research to commercialisation.